Literature DB >> 11157913

New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin.

B B Ba1, A Bernard, A Iliadis, C Quentin, D Ducint, R Etienne, M Fourtillan, I Maachi-Guillot, M C Saux.   

Abstract

An in vitro pharmacodynamic model using a disposable dialyser unit and computer-controlled devices was developed. Feedback control of peristaltic pump flow rates is used to maintain constant flow rates, thus avoiding the problem of the modification of the physical properties of the tubing that generally occurs. Fast equilibrium is obtained with capillaries, which allows simulation of the same kinetic profile in the central and the peripheral compartments. Thus, more accurate simulation of plasma, extracapillary fluid or whole tissue kinetics can be performed. Our model was validated by simulation of a 30 min infusion of a 200 mg dose, and of an oral administration of a 500 mg dose of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157913     DOI: 10.1093/jac/47.2.223

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

Authors:  Yuan-Cheng Chen; Wang Liang; Jia-Li Hu; Gao-Li He; Xiao-Jie Wu; Xiao-Fang Liu; Jing Zhang; Xue-Qian Hu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-30       Impact factor: 2.745

2.  Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Authors:  Boubakar B Ba; Corinne Arpin; Branly Bikie Bi Nso; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

3.  Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.

Authors:  Boubakar B Ba; Corinne Arpin; Céline Vidaillac; Arnaud Chausse; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.